$5 Billion Bond Measure: California Stem Cell Agency Sets a Course to Secure Its Financial Future
By David Jensen,
California Stem Cell Report
| 12. 14. 2017
Directors of the California stem cell agency today virtually endorsed a plan to stave off its financial death, pinning their hopes on a possible $5 billion bond measure and a private fundraising effort to bring in an additional $222 million.
The California Institute for Regenerative Medicine (CIRM), as the agency is formally known, expects to run out of cash for new awards in late 2019 because of limits in the ballot measure that created it in 2004.
Robert Klein, who led the 2004 initiative campaign, appeared before the governing board meeting and touted the new bond proposal. The Palo Alto real estate investment banker told directors that California had a "moral imperative" to continue its stem cell work. He said,
"This is California’s contribution to the future of medicine....This is the bridge to the future of health care."
No vote was taken on endorsement of a ballot measure that has yet to be written or qualified for the ballot. But no objection was raised by board members to moving forward on what Thomas called the best option.
Under...
Related Articles
By Azeen Ghorayshi and Sarah Kliff, The New York Times | 08.12.2024
An emerging movement against in vitro fertilization is driving some doctors and patients in red states to move or destroy frozen embryos.
The embryo migration is most striking in Alabama, where the State Supreme Court ruled in February that embryos...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Amanda Becker and Shefali Luthra, The 19th | 07.08.2024
Image by Duke University Archives from Flickr
Republicans have adopted a slate of policy positions ahead of next week’s convention that does not call for a federal legislative abortion ban, but opens the door to establishing fetal personhood.
The Republican...
By Beth Duff-Brown, Stanford Institute for Economic Policy Research | 07.12.2024
The debate over in vitro fertilization (IVF) has become a hot-button policy and political issue, despite the medical procedure to help people become pregnant having been mainstream in the United States for nearly half a century.
The Alabama Supreme Court ...